Literature DB >> 10797379

Expression of capsid [correction of caspid] protein VP1 for use as antigen for the diagnosis of enterovirus 71 infection.

S R Shih1, Y S Li, C C Chiou, P C Suen, T Y Lin, L Y Chang, Y C Huang, K C Tsao, H C Ning, T Z Wu, E C Chan.   

Abstract

To produce enterovirus 71 antigen for diagnostic purposes, the gene encoding the entire capsid protein VP1 was amplified by reverse transcription-polymerase chain reaction (RT-PCR), cloned and expressed in Escherichia coli as a poly-histidine fusion protein. Western blotting experiments with sera from patients with enterovirus 71 infection indicated that immunoglobulin G (IgG) and IgM antibodies bound to a single polypeptide VP1. According to these results, IgM anti-VP1 appeared in sera of patients with a symptomatic enterovirus 71 acute infection, whereas IgG anti-VP1 was present in sera of past infection. This finding suggests that detecting IgG and IgM immune responses against linear epitopes of recombinant VP1 is an effective means of determining the different phases of enterovirus 71 infection. In addition, sera containing coxsackie virus 16 (CA16) antibodies did not cross-react with the recombinant VP1 of enterovirus 71, despite the homology between VP1 proteins of both viruses. Comparison with reference PCR and neutralization assays showed these antibody tests to be appropriate for the serodiagnosis of enterovirus 71 infection. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797379     DOI: 10.1002/(sici)1096-9071(200006)61:2<228::aid-jmv9>3.0.co;2-r

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Genetic analysis of the P1 region of human enterovirus 71 strains and expression of the 55 F strainVP1 protein.

Authors:  Jian-qiang Li; Jun-jie Yang; Xiu-juan Fan; Zhen-peng Sun; Yan Sun; Huan Li; Zi-xin Meng; Wei Li
Journal:  Virol Sin       Date:  2012-01-22       Impact factor: 4.327

2.  Identification of specific antigenic epitope at N-terminal segment of enterovirus 71 (EV-71) VP1 protein and characterization of its use in recombinant form for early diagnosis of EV-71 infection.

Authors:  Jianhua Zhang; Bingfu Jiang; Mingjie Xu; Xing Dai; Michael A Purdy; Jihong Meng
Journal:  Virus Res       Date:  2014-06-19       Impact factor: 3.303

Review 3.  Therapeutic and prevention strategies against human enterovirus 71 infection.

Authors:  Chee Choy Kok
Journal:  World J Virol       Date:  2015-05-12

4.  Enterovirus 71 infection impairs the reproductive capacity of female mice.

Authors:  Bo Qin; Qiuyue Yan; Xing Chen; Xiuping Xu; Yanan Wang; Jinkun Chen; Xuejun Dong
Journal:  Exp Ther Med       Date:  2017-05-23       Impact factor: 2.447

5.  Comparing Enterovirus 71 with Coxsackievirus A16 by analyzing nucleotide sequences and antigenicity of recombinant proteins of VP1s and VP4s.

Authors:  Yuyun Li; Runan Zhu; Yuan Qian; Jie Deng; Yu Sun; Liying Liu; Fang Wang; Linqing Zhao
Journal:  BMC Microbiol       Date:  2011-11-03       Impact factor: 3.605

6.  Expression of enterovirus 71 capsid protein VP1 in Escherichia coli and its clinical application.

Authors:  Mei Shi; Yaping Zhou; Limin Cao; Cuijun Ding; Yun Ji; Qinbo Jiang; Xiping Liu; Xiang Li; Xueling Hou; Hongjun Peng; Weifeng Shi
Journal:  Braz J Microbiol       Date:  2014-03-10       Impact factor: 2.476

Review 7.  Enterovirus A71: virulence, antigenicity, and genetic evolution over the years.

Authors:  Sheng-Wen Huang; Dayna Cheng; Jen-Ren Wang
Journal:  J Biomed Sci       Date:  2019-10-21       Impact factor: 8.410

8.  A practical method for evaluating the in vivo efficacy of EVA-71 vaccine using a hSCARB2 knock-in mouse model.

Authors:  Yong Wu; Zhe Qu; Rui Xiong; Yanwei Yang; Susu Liu; Jianhui Nie; Chunnan Liang; Weijin Huang; Youchun Wang; Changfa Fan
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

9.  VP1 of Enterovirus 71 Protects Mice Against Enterovirus 71 and Coxsackievirus B3 in Lethal Challenge Experiment.

Authors:  Fang-Hong Chen; Xiong Liu; Hua-Li Fang; Nan Nan; Zhan Li; Nian-Zhi Ning; De-Yan Luo; Tao Li; Hui Wang
Journal:  Front Immunol       Date:  2019-11-08       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.